3:38 PM
 | 
Jan 09, 2019
 |  BC Extra  |  Clinical News

Opdivo meets OS endpoint in esophageal cancer trial

Ono Pharmaceutical Co. Ltd. (Tokyo:4528) said anti-PD-1 mAb Opdivo nivolumab met the primary endpoint vs. chemotherapy of improving overall survival in the Phase III ATTRACTION-3 trial to treat esophageal cancer.

Ono said Opdivo is the first checkpoint inhibitor to significantly extend OS in patients with PD-L1 unselected, unresectable advanced or recurrent esophageal cancer. The company, which did not report detailed data, plans to present additional data at a scientific meeting.

The open-label, international trial enrolled about 390 patients refractory to or intolerant of one prior combination therapy with fluoropyrimidine and platinum-based therapy.

Opdivo, which is partnered with Bristol-Myers Squibb Co. (NYSE:BMY), is not yet approved to treat esophageal cancer in any country.

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD